FMR LLC's Form 4 filing
Beam Therapeutics Inc. (BEAM) · filed Aug 8, 2022
- Accession no.
- 0000315066-22-001678
- Filed
- Aug 8, 2022
- Trade date
- Aug 4-5, 2022
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 9 non-derivative transactions. Open-market sales total $1.23M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| FMR LLCCIK 0000315066 | 10% Owner, Other: See Remark 1 |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 4, 2022 | Common Stock | JOtherDisposed | −800,000 | $0.00 | $0 | 2,135,511 | Indirect | |
| Aug 4, 2022 | Common Stock | JOtherAcquired | +375,536 | $0.00 | $0 | 375,536 | Indirect | |
| Aug 4, 2022 | Common Stock | JOtherDisposed | −375,369 | $0.00 | $0 | 167 | Indirect | |
| Aug 4, 2022 | Common Stock | JOtherAcquired | +180,366 | $0.00 | $0 | 193,184 | Indirect | |
| Aug 4, 2022 | Common Stock | JOtherDisposed | −167,564 | $0.00 | $0 | 25,620 | Indirect | |
| Aug 4, 2022 | Common Stock | JOtherAcquired | +20,159 | $0.00 | $0 | 20,159 | Indirect | |
| Aug 4, 2022 | Common Stock | JOtherAcquired | +312,512 | $0.00 | $0 | 2,803,027 | Indirect | |
| Aug 5, 2022 | Common Stock | SSaleDisposed | −167 | $61.00 | −$10,187 | 0 | Indirect | |
| Aug 5, 2022 | Common Stock | SSaleDisposed | −20,159 | $60.50 | −$1,219,619.5 | 0 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.
Remarks
Remark 1: Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. The address of Abigail P. Johnson is c/o FMR LLC, 245 Summer Street, Boston, MA 02110. Remark 2: The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the undersigned are the beneficial owners of any securities reported herein. Remark 3: The general partner of F-Prime Capital Partners Healthcare Fund V LP is F-Prime Capital Partners Healthcare Advisors Fund V LP (FPCPHA). FPCPHA is solely managed by Impresa Management LLC, the general partner of its general partner and its investment manager. Impresa Fund III Limited Partnership is solely managed by Impresa Management LLC, its general partner and investment manager. Impresa Management LLC is owned, directly or indirectly, by various shareholders and employees of FMR LLC, including certain members of the Johnson family. F-Prime Inc. is a wholly-owned subsidiary of FMR LLC.